Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Melanoma 1Carcinoma, Squamous Cell 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × tilsotolimod × Clear all
NCT04196283 2023-02-27

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

AbbVie

Phase 1 Completed
30 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms

NCT03052205 2020-02-11

ILLUMINATE-101

Idera Pharmaceuticals, Inc.

Phase 1 Completed
54 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡